Engineered immune cells take aim at rare, Hard-to-Treat cancers

NCT ID NCT07467122

First seen Mar 20, 2026 · Last updated Jun 16, 2026 · Updated 11 times

Summary

This early-phase study tests a personalized cell therapy for people with advanced mesenchymal cancers (like certain sarcomas) that have stopped responding to standard treatments. Researchers take a patient's own immune cells, engineer them to recognize a protein called MAGE-A4 found on cancer cells, and infuse them back. The main goals are to check safety and see if the treatment can shrink tumors. About 15 adults aged 18-75 will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MESENCHYMAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sun Yat-sen Memorial Hospital

    RECRUITING

    Guangzhou, Guangdong, 510120, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.